Related references
Note: Only part of the references are listed.Induction of MGMT expression is associated with temozolomide resistance in glioblastoma xenografts
Gaspar J. Kitange et al.
NEURO-ONCOLOGY (2009)
A multicenter cohort study of dose-dense temozolomide (21 of 28 days) for the treatment of recurrent anaplastic astrocytoma or oligoastrocytoma
Bart Neyns et al.
CANCER INVESTIGATION (2008)
Mechanisms of chemoresistance to alkylating agents in malignant glioma
Jann N. Sarkaria et al.
CLINICAL CANCER RESEARCH (2008)
Dose translation from animal to human studies revisited
Shannon Reagan-Shaw et al.
FASEB JOURNAL (2008)
The added value of concurrently administered temozolomide versus adjuvant temozolomide alone in newly diagnosed glioblastoma
David J. Sher et al.
JOURNAL OF NEURO-ONCOLOGY (2008)
Efficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma
Antje Wick et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Temozolomide in glioblastoma: results of administration at first relapse and in newly diagnosed cases. Is still proposable an alternative schedule to concomitant protocol?
Manuela Caroli et al.
JOURNAL OF NEURO-ONCOLOGY (2007)
Correlation between O6-methylguanine-DNA methyltransferase and survival in inoperable newly diagnosed glioblastoma patients treated with neoadjuvant temozolomide
Olivier L. Chinot et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Apoptosis in malignant glioma cells triggered by the temozolomide-induced DNA lesion O-6-methylguanine
W. P. Roos et al.
ONCOGENE (2007)
Use of an orthotopic xenograft model for assessing the effect of epidermal growth factor receptor amplification on glioblastoma radiation response
JN Sarkaria et al.
CLINICAL CANCER RESEARCH (2006)
O6-methylguanine DNA methyltransferase and p53 status predict temozolomide sensitivity in human malignant glioma cells
M Hermisson et al.
JOURNAL OF NEUROCHEMISTRY (2006)
How lymphotoxic is dose-intensified temozolomide? The glioblastoma experience
W Wick et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Randomized phase II study of temozolomide and radiotherapy compared with radiotherapy alone in newly diagnosed glioblastoma multiforme
H Athanassiou et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Patient tumor EGFR and PDGFRA gene amplifications retained in an invasive intracranial xenograft model of glioblastoma multiforme
C Giannini et al.
NEURO-ONCOLOGY (2005)
MGMT gene silencing and benefit from temozolomide in glioblastoma
ME Hegi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma
R Stupp et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
CpG island hypermethylation of the DNA repair enzyme methyltransferase predicts response to temozolomide in primary gliomas
MF Paz et al.
CLINICAL CANCER RESEARCH (2004)
One week on/one week off:: A novel active regimen of temozolomide for recurrent glioblastoma
W Wick et al.
NEUROLOGY (2004)
Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules
AW Tolcher et al.
BRITISH JOURNAL OF CANCER (2003)
Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents
M Esteller et al.
NEW ENGLAND JOURNAL OF MEDICINE (2000)
Unmasking a killer:: DNA O6-methylguanine and the cytotoxicity of methylating agents
M Bignami et al.
MUTATION RESEARCH-REVIEWS IN MUTATION RESEARCH (2000)
A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse
WKA Yung et al.
BRITISH JOURNAL OF CANCER (2000)
Share Paper
